Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
NCT02869243: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients	Completed	1	15	Europe, RoW	hrBMP4, Recombinant Bone Morphogenic Protein-4, Device:Intracranial Catheter	Stemgen, ORION Clinical Services	Glioblastoma	10/20	06/21
HS215 / Stemgen
No trials found
HS216 / Stemgen
No trials found
HS217 / Stemgen
No trials found
HS219α&β / Stemgen
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
recombinant human bone morphogenetic protein 4 (HS214) / Stemgen
NCT02869243: A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients	Completed	1	15	Europe, RoW	hrBMP4, Recombinant Bone Morphogenic Protein-4, Device:Intracranial Catheter	Stemgen, ORION Clinical Services	Glioblastoma	10/20	06/21
HS215 / Stemgen
No trials found
HS216 / Stemgen
No trials found
HS217 / Stemgen
No trials found
HS219α&β / Stemgen
No trials found